News
LUMO
--
0.00%
--
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in September
GlobeNewswire · 08/27 14:00
Lumos Pharma, Inc. 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2020 Q2 earnings call.
Seekingalpha · 08/14 16:51
Lumos Pharma Q2 EPS $(0.65) Up From $(2.47) YoY, Sales $33.00K
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.65) per share. This is a 73.68 percent increase over losses of $(2.47) per share from the same period last year. The company reported $33.00 thousand in sales
Benzinga · 08/13 20:10
Lumos Pharma EPS beats by $0.05
Lumos Pharma (LUMO): Q2 GAAP EPS of -$0.65 beats by $0.05.Revenue of $0.03MPress Release
Seekingalpha · 08/13 20:03
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 12:18
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2020 financial results after market close
GlobeNewswire · 07/28 20:01
Lumos Pharma shares are trading higher after the company announced the sale of its Priority Review Voucher for $100 million. UPDATE: Shares have since reversed, now lower.
Benzinga · 07/28 14:01
TCOM, PII among premarket gainers
Seeking Alpha · 07/28 12:16
SPPI, TESS, CRMD and ADMS among after-hours movers
Seeking Alpha · 07/27 21:45
Lumos rises on sale of its priority voucher rights for $60M
Seeking Alpha · 07/27 21:12
Lumos Pharma shares are trading higher after the company announced the sale of its Priority Review Voucher for $100 million.
Benzinga · 07/27 20:08
Lumos Pharma Reports Sale Of Priority Review Voucher For $100M
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.
Benzinga · 07/27 20:07
Lumos Pharma Announces Sale of Priority Review Voucher
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review
GlobeNewswire · 07/27 20:05
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Simply Wall St. · 06/19 13:21
Is Lumos Pharma, Inc. (LUMO) A Good Stock To Buy?
Insider Monkey · 06/10 20:41
Lumos Pharma Q1 EPS $(0.14) May Not Compare To $(0.82) Estimate
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.82) by 82.93 percent.
Benzinga · 05/28 20:02
Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds.
GlobeNewswire · 05/28 20:01
Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference
GlobeNewswire · 05/27 21:27
Lumos Pharma to Report First Quarter 2020 Financial Results and Host a Conference Call on May 28, 2020
Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2020 financial results after market close on Thursday, May 28, 2020. The company will host a conf
GlobeNewswire · 05/26 14:36
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning session, 85 stocks hit new 52-week highs.
Benzinga · 05/20 14:38
Webull provides a variety of real-time LUMO stock news. You can receive the latest news about Lumos Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LUMO
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
More